Apriori is working to create a world where humanity is protected against viral threats. Our pioneering approach centers on a unique technology platform, which allows us to survey the entire landscape of existing and potential viral variants to design new vaccines and antibody drugs against the most threatening variants. Octavia can also inform public health policy in real time by predicting the impact of emerging variants. Apriori was founded in 2020 in Flagship Labs, a unit of Flagship Pioneering.
| Website | http://aprioribio.com |
| Revenue | $64.1 million |
| Employees | 23 (20 on RocketReach) |
| Industry | Biotechnology |
| Competitors | Strateos, Zymergen, Inc., Synthace, Elekta, Geneious, Boehringer Ingelheim, Benchling, Sestina Bio, LLC., Paradigm Biopharmaceuticals, Evonetix Ltd +42 more (view full list) |
Looking for a particular Apriori Bio employee's phone or email?
Apriori Bio Questions
The Apriori Bio annual revenue was $64.1 million in 2026.
Harry Kleanthous is the Chief Scientific Officer of Apriori Bio.
20 people are employed at Apriori Bio.
Top Apriori Bio Employees
-
Harry Kleanthous
Chief Scientific Officer at Apriori Bio
Chelmsford, MA, US23 -
Max Winston
Senior Director of Data Science at Apriori Bio
Cambridge, MA, US25 -
14
-
23
-
David Chiovitti
Senior Scientist II Automation at Apriori Bio
Massachusetts, United States11 -
Timothy Coulther
Senior Scientist at Apriori Bio
Boston, MA, US13 -
Roberto Nunes
Senior Research Associate at Apriori Bio
Boston, MA, US22
Related Companies
